EU GMP ANNEX 1 · 2022 REVISION · EFFECTIVE 25 AUG 2023
EU GMP Annex 1 Blister Packaging Compliance Complete Technical Guide for Pharmaceutical Manufacturers
The 2022 revision of EU GMP Annex 1 introduced mandatory Contamination Control Strategy (CCS), expanded Quality Risk Management requirements, and redefined equipment design standards. This guide covers everything blister packaging manufacturers need to comply.
59-Page 2022 Revision Decoded
CCS Templates Included
20+ Years EU GMP Experience
Audit-Ready Documentation
Annex 1 Ready
2022 Revision Compliant
2022 Revision Compliant
EU GMP Annex 1 — Quick Reference
EU GMP Annex 1 (EudraLex Volume 4) is the European Union's Good Manufacturing Practice guideline for sterile medicinal products. The 2022 revision was published on 25 August 2022 and became fully effective on 25 August 2023, introducing mandatory Contamination Control Strategy and expanded equipment requirements.
- Document: EudraLex Volume 4, Annex 1 — "Manufacture of Sterile Medicinal Products"
- Publisher: European Commission, Directorate-General for Health and Food Safety
- Current Revision: 2022 (replaces 2008 version, expanded from 16 to 59 pages)
- Effective Date: 25 August 2023 (lyophilization section: 25 August 2024)
- Scope: All sterile medicinal product manufacture, including aseptic processing, terminal sterilization, sterile packaging, and sterile finishing
- Key New Requirement: Mandatory written Contamination Control Strategy (CCS) covering all factors affecting sterility and contamination control
- Cleanroom Grades: Grade A (≤3,520 particles ≥0.5μm/m³), Grade B, Grade C, Grade D — defined per ISO 14644-1 alignment
- Quality Framework: Mandatory integration with ICH Q9 (QRM) and ICH Q10 (PQS)
- Equipment Section: Section 4 — design, qualification, cleaning, sterilization, monitoring
- Applicable to Blister Packaging: Yes, when packaging sterile or aseptically-prepared products (pre-filled syringes, sterile devices, ophthalmic products)
Source: European Commission, EudraLex Volume 4, Annex 1 (Revision 2022). Published by HIJ Machinery (Wenzhou) — Founder Forester Xiang has 20+ years of EU GMP-aligned blister packaging machinery design experience and has supported 100+ pharmaceutical facility audits across 30+ countries. All HIJ blister packaging machines are designed to comply with EU GMP Annex 1, WHO GMP, and cGMP requirements.
Annex 1 — Evolution & Key Milestones
From 1972 to 2024, EU GMP Annex 1 has evolved from 4 pages of basic requirements to a 59-page comprehensive standard. Understanding the timeline helps contextualize current obligations.
1972
First Annex 1
Initial sterile manufacturing GMP guidance published (4 pages).
2008
Major Revision
Expanded to 16 pages. Defined cleanroom grades A–D, BFS guidance.
2022
Current Revision
Published 25 Aug 2022. 59 pages. CCS, QRM, PQS integrated.
2024
Lyo Effective
25 Aug 2024 — lyophilization section fully effective.
8 Major Changes in Annex 1 (2022 Revision)
Key differences vs. the 2008 version that every blister packaging manufacturer must address.
1
Mandatory Contamination Control Strategy (CCS)
Section 2 introduces an entirely new requirement: a documented, holistic CCS covering facility design, equipment, personnel, materials, and continuous monitoring. CCS must be approved, periodically reviewed, and updated based on data trends.
2
Quality Risk Management (QRM) Integration
Explicit alignment with ICH Q9 throughout the document. QRM must drive CCS development, equipment qualification scope, environmental monitoring frequency, and change control decisions. FMEA, HACCP, and FTA are recommended tools.
3
Pharmaceutical Quality System (PQS) Alignment
Reference to ICH Q10 integrated. Annex 1 now requires documented PQS covering deviation management, CAPA, change control, knowledge management, and lifecycle approach to equipment and process validation.
4
Pre-Use Post-Sterilization Integrity Testing (PUPSIT)
For sterilizing-grade filters in aseptic processing, PUPSIT is now explicitly recommended. Must be justified through QRM if not implemented. Significant impact on liquid blister and pre-filled syringe lines.
5
Expanded Environmental Monitoring
Section 9 dramatically expanded. Continuous monitoring of Grade A and B areas required. Settle plates, contact plates, active air sampling, and particle monitoring must align with risk-based frequencies defined in CCS.
6
Modernized Barrier Technology Guidance
Detailed requirements for RABS (Restricted Access Barrier Systems) and isolators. Strong preference signaled for closed-system processing. Open processing must justify alternatives via QRM.
7
Lyophilization Section Expanded
New dedicated section (effective 25 Aug 2024). Requirements for loading/unloading, vial handling, transfer systems, and integrity testing of lyophilized products. Critical for sterile blister-packed lyophilized products.
8
Container Closure Integrity (CCI)
Stronger emphasis on CCI testing throughout product lifecycle. Methods must be validated and capable of detecting defects relevant to product. For blister packaging: seal integrity, leak testing, dye penetration, and vacuum decay are common methods.
Contamination Control Strategy (CCS)
The most significant new requirement in Annex 1 (2022). A documented holistic approach covering all 12 elements that affect product sterility and contamination.
Annex 1 Section 2 mandates a documented Contamination Control Strategy (CCS) that "defines all critical control points and assesses the effectiveness of all controls" for contamination prevention. The CCS is a living document — approved, regularly reviewed, and updated based on environmental monitoring data, deviations, and continuous improvement initiatives. For blister packaging operations handling sterile products, CCS is the foundation of audit defense.
1. Plant Design
Facility layout, room classifications, airlocks, material/personnel flow patterns.
2. Equipment
Blister machine design, materials, qualification, cleaning validation, sterilization.
3. Utilities
HVAC, water systems (WFI, PW), compressed air, gases — quality and monitoring.
4. Raw Materials
API, excipients, primary packaging (PVC, foil), supplier qualification, bioburden control.
5. Personnel
Gowning procedures, training, behavior in classified areas, qualification programs.
6. Process & Product
Process design, hold times, in-process controls, batch size justification.
7. Validation
DQ/IQ/OQ/PQ, cleaning validation, media fill, sterilization validation lifecycle.
8. Monitoring
Environmental monitoring (viable + non-viable), trend analysis, alert/action limits.
9. Cleaning & Disinfection
Cleaning agents rotation, disinfection efficacy, sporicidal program, residue limits.
10. Vendor Management
Supplier audits, technical agreements, quality agreements, ongoing oversight.
11. Maintenance
Preventive maintenance, calibration, parts qualification, change control integration.
12. Continuous Improvement
Periodic CCS review, data trending, deviation/CAPA closure, knowledge management.
Cleanroom Grades for Blister Packaging Operations
Annex 1 defines four cleanroom grades. Selection depends on product sterility status and packaging stage.
| Grade | At Rest (≥0.5μm/m³) | In Operation (≥0.5μm/m³) | Microbial Limit (CFU/m³) | Typical Blister Use |
|---|---|---|---|---|
| Grade A | 3,520 | 3,520 | <1 | Aseptic filling/sealing of sterile pre-filled syringes |
| Grade B | 3,520 | 352,000 | 10 | Background for Grade A aseptic blister operations |
| Grade C | 352,000 | 3,520,000 | 100 | Preparation areas for sterile blister packaging |
| Grade D | 3,520,000 | Not defined | 200 | Terminally sterilized blister packs, secondary packaging |
For non-sterile pharmaceutical blister packaging (most oral solid dosage forms): EU GMP Part I applies, typically operating in Grade D or Controlled Non-Classified (CNC) environments. However, Annex 1 principles—particularly CCS framework, QRM-based monitoring, and documented equipment qualification—are increasingly adopted as best practice across all pharmaceutical packaging operations regardless of sterility status. HIJ blister packaging machines are designed to support both sterile (Grade A/B/C) and non-sterile (Grade D/CNC) operations.
Annex 1 Section 4 — Equipment Requirements Decoded
Specific design, qualification, and operational requirements for blister packaging equipment.
Design Requirements
- Materials: Product contact surfaces — AISI 316L stainless steel or equivalent inert, non-reactive material
- Surface finish: Ra ≤0.8μm for product contact (electropolished preferred for sterile applications)
- Cleanability: Smooth surfaces, no crevices, accessible disassembly, no horizontal ledges
- CIP/SIP: Capability where required by product type and process
- Drainage: Self-draining design, no dead legs, sloped surfaces
- Lubricants: Food-grade or pharmaceutical-grade only on contact-adjacent components
Qualification Requirements
- URS: User Requirement Specification — risk-based, traceable to CCS
- DQ: Design Qualification reviewing supplier specifications against URS
- IQ: Installation Qualification — verifies as-built matches design
- OQ: Operational Qualification — operating parameters within specifications
- PQ: Performance Qualification — sustained performance during routine operation
- Periodic review: Re-qualification triggered by changes, per CCS schedule
Cleaning & Sterilization
- Cleaning validation: Worst-case product, residue limits per ICH Q3D
- Sterilization methods: Steam, dry heat, irradiation, chemical (validated)
- Sporicidal program: Required for Grade A/B environments, rotational schedule
- Hold times: Validated maximum dirty hold time and clean hold time
- Re-cleaning trigger: Defined criteria for re-cleaning before campaign restart
Monitoring & Controls
- EM ports: Built-in environmental monitoring sample ports for Grade A zones
- Continuous monitoring: Particle counters, temperature, RH%, differential pressure
- Audit trail: 21 CFR Part 11 / EU Annex 11 compliant electronic records
- Alarm system: Real-time alerts for critical parameter excursions
- Calibration: Documented schedule, certified standards, deviation tracking
- Data integrity: ALCOA+ principles applied to all electronic records
How HIJ Blister Machines Meet Section 4
All HIJ blister packaging machines feature AISI 316L product contact surfaces (Ra ≤0.8μm), modular disassembly design, optional CIP/SIP capability, integrated EM ports, 21 CFR Part 11-ready electronic records, and complete URS/DQ/IQ/OQ/PQ documentation aligned with Annex 1.
Annex 1 Qualification Roadmap — 16 to 24 Weeks
Realistic timeline from URS to PQ sign-off for a new EU GMP Annex 1 compliant blister packaging line.
W1-3URS
User Requirement Specification (URS) Development
Define product type, output speed, materials, compliance scope, integration with CCS. Risk-based requirements aligned with ICH Q9. Approved by QA, Production, Engineering.
Deliverable: Approved URS DocumentW4-5DQ
Design Qualification (DQ)
Review supplier technical specifications, P&IDs, GA drawings against URS. Verify materials of construction, surface finish, CIP/SIP design, EM port locations. QRM-based gap analysis.
Deliverable: DQ Report with Sign-offW6-7FAT
Factory Acceptance Test (FAT)
Witness testing at HIJ Wenzhou facility. Functional verification, simulated production runs, control system validation, documentation review. Customer team participation required.
Deliverable: Signed FAT Protocol & PunchlistW8-13Ship
Shipment & Customs
FOB Wenzhou shipping (3–6 weeks depending on destination). Customs clearance, transport to facility, uncrating inspection. Concurrent: site preparation, utility installation.
Deliverable: Equipment On-Site & InspectedW14-15IQ
Installation Qualification (IQ)
Verify installation matches design. Component identification, utility connections, calibration certificates, software version verification, documentation completeness.
Deliverable: IQ Report ApprovedW16-19OQ
Operational Qualification (OQ)
Verify operating parameters within specifications. Test all functions, alarms, interlocks, range testing, control system validation. Includes media fill simulation for sterile applications.
Deliverable: OQ Report ApprovedW20-24PQ
Performance Qualification (PQ) + CCS Integration
Three consecutive successful production batches under routine conditions. Environmental monitoring qualification. CCS integration documentation. Final regulatory release for commercial production.
Deliverable: PQ Report + Production AuthorizationWhy HIJ for EU GMP Annex 1 Compliance
20+ years of EU GMP-aligned engineering. Direct experience with EMA-inspected facilities. Audit-ready documentation.
Complete Annex 1 Documentation Package
URS templates, DQ/IQ/OQ/PQ protocols, FAT/SAT scripts, CCS framework documents, validation master plan templates — all aligned with Annex 1 (2022 revision).
Section 4 Compliant Design
AISI 316L stainless steel product contact, surface finish Ra ≤0.8μm, modular disassembly, optional CIP/SIP, integrated EM ports, 21 CFR Part 11-ready electronic records.
QRM-Based Engineering
Every machine engineered with documented FMEA risk assessments per ICH Q9. Critical control points identified, mitigation built into design, traceable to URS requirements.
On-Site Validation Support
HIJ engineers travel globally to support IQ/OQ/PQ execution. Audit defense preparation. Pre-EMA inspection readiness reviews. Post-deployment compliance support.
CCS Framework Templates
Pre-built Contamination Control Strategy templates covering all 12 elements per Annex 1 Section 2. Customizable for your specific blister line and product portfolio.
Forester's EU GMP Expertise
Founder Forester Xiang has audited EMA-inspected facilities in EU, India, Southeast Asia. Direct knowledge of inspector expectations and common audit findings.
20+
Years EU GMP Experience
100+
Pharma Audits Supported
30+
Countries Including EU
59
Annex 1 Pages Mapped
20+ Years
EU GMP Expertise
Forester Xiang on Annex 1
FOUNDER & CEO · HIJ MACHINERY
The biggest mistake I see pharmaceutical manufacturers make with the 2022 Annex 1 revision is treating CCS as a documentation exercise. It is not. CCS is the operational philosophy. Your blister packaging line, your environmental monitoring, your cleaning program, your training records — all flow from CCS. Get the CCS right first, and the rest of Annex 1 compliance becomes systematic. Get it wrong, and you'll be patching audit findings for years.
— Forester Xiang, after auditing 100+ pharmaceutical facilities across 30+ countries including EMA-inspected sites
EU GMP Annex 1 — Frequently Asked Questions
Direct answers to the most-searched questions about Annex 1 compliance for blister packaging.
What is EU GMP Annex 1 and when did it come into effect?
EU GMP Annex 1 is the European Union's GMP guideline for the manufacture of sterile medicinal products, part of EudraLex Volume 4. The current revision was published 25 August 2022 and became fully effective 25 August 2023 (lyophilization section: 25 August 2024). It introduces mandatory Contamination Control Strategy (CCS), Quality Risk Management (QRM) integration, and significantly expanded equipment requirements.
Does EU GMP Annex 1 apply to blister packaging machines?
Yes, when used for sterile or aseptically prepared products — pre-filled syringes, sterile medical devices, ophthalmic products. For non-sterile oral solid dosage blister packaging, EU GMP Part I and Annex 15 apply, but Annex 1 principles (CCS, QRM) are increasingly adopted as best practice.
What is a Contamination Control Strategy (CCS) under Annex 1?
A CCS is a documented, holistic approach required by Annex 1 Section 2 covering all factors affecting product sterility. For blister packaging, CCS must address: facility design, equipment, personnel, utilities, raw materials, environmental monitoring, cleaning, vendor management, validation, maintenance, and continuous improvement — 12 elements total.
What cleanroom grade is required for blister packaging under Annex 1?
Depends on product type. Terminally sterilized products: Grade D minimum. Aseptic packaging: Grade A in critical zones (≤3,520 particles ≥0.5μm/m³, unidirectional airflow 0.36–0.54 m/s) within Grade B background. Non-sterile blister packaging: typically Grade D or Controlled Non-Classified (CNC) per EU GMP Part I.
What equipment design requirements does Annex 1 impose on blister machines?
Annex 1 Section 4 requires: AISI 316L product contact (Ra ≤0.8μm), design-for-cleaning, optional CIP/SIP, integrated EM ports, 21 CFR Part 11-compliant records, and full DQ/IQ/OQ/PQ qualification. HIJ blister packaging machines meet all these requirements with complete documentation.
Are HIJ blister packaging machines compliant with EU GMP Annex 1?
Yes. All HIJ blister packaging machines are designed to meet Annex 1 (2022 revision). Features: AISI 316L contact surfaces, modular disassembly design, optional CIP/SIP, EM port integration, 21 CFR Part 11-ready electronic records, complete DQ/IQ/OQ/PQ documentation, and CCS framework templates aligned with Annex 1 Section 2.
How does Annex 1 (2022) differ from the 2008 revision?
Expanded from 16 to 59 pages. Major additions: (1) Mandatory CCS (entirely new), (2) Explicit QRM/ICH Q9 integration, (3) PUPSIT for sterilizing filters, (4) Expanded environmental monitoring, (5) ICH Q10 PQS alignment, (6) Modernized RABS/isolator guidance, (7) Detailed lyophilization, (8) Container Closure Integrity emphasis.
What is Quality Risk Management (QRM) under Annex 1?
QRM, aligned with ICH Q9, is a systematic process for assessment, control, communication, and review of risks across product lifecycle. Common tools: FMEA, HACCP, FTA, Risk Ranking. QRM outputs inform equipment design, validation scope, and routine monitoring frequencies.
How long does Annex 1 compliance qualification take for a blister line?
Typically 16–24 weeks: URS (2–3 weeks), DQ (2 weeks), FAT (1–2 weeks), shipping (3–6 weeks), IQ (1–2 weeks), OQ (3–4 weeks), PQ (4–6 weeks), CCS integration (concurrent 4–6 weeks). HIJ provides full documentation support throughout.
What documentation does an Annex 1 audit require for blister packaging?
Approved CCS, URS, DQ/IQ/OQ/PQ reports, cleaning validation, environmental monitoring data with trends, training records, change control logs, deviation/CAPA records, equipment-specific FMEA risk assessments, and supplier qualification documentation.
Ready for Annex 1 Compliant Blister Packaging?
Get HIJ's complete EU GMP Annex 1 documentation package — URS templates, CCS framework, validation protocols, and audit-ready evidence binder. Designed by 20+ years of EU GMP expertise.
Annex 1 (2022) Compliant
CCS Templates
QRM-Based Engineering
Full DQ/IQ/OQ/PQ
On-Site Validation
24-Hour Response
HIJ Machinery (Wenzhou) · Pharmaceutical Blister Packaging Machinery Manufacturer
Founder: Forester Xiang · 20+ Years EU GMP Experience · 100+ Pharmaceutical Facility Audits · 30+ Countries
Compliance: EU GMP Annex 1 (2022) · WHO GMP TRS 961 · cGMP 21 CFR Parts 210/211 · CE Directive 2006/42/EC
Reference Source: European Commission, EudraLex Volume 4, Annex 1 — Manufacture of Sterile Medicinal Products, Revision 2022
Founder: Forester Xiang · 20+ Years EU GMP Experience · 100+ Pharmaceutical Facility Audits · 30+ Countries
Compliance: EU GMP Annex 1 (2022) · WHO GMP TRS 961 · cGMP 21 CFR Parts 210/211 · CE Directive 2006/42/EC
Reference Source: European Commission, EudraLex Volume 4, Annex 1 — Manufacture of Sterile Medicinal Products, Revision 2022